Drug intelligence / Profile preview

APX005M + cabiralizumab

Development stage: Unknown
Lead developer: Pyxis Oncology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

APX005M + cabiralizumab is a combination immunotherapy approach that pairs a CD40 agonistic monoclonal antibody (APX005M) with a CSF1R-targeting antibody (cabiralizumab). This dual macrophage-polarizing therapy aims to enhance anti-tumor immune responses by simultaneously activating antigen-presenting cells and blocking tumor-associated macrophage recruitment and function.

Targets

CD40 (Cluster of differentiation 40 receptor)CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on APX005M + cabiralizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APX005M + cabiralizumab.

Explore the full profile